Suppl Sample Clauses

Suppl. Annuity Tax 1.86% 1.64% 1.74% 1.60% 1.66% 0.00% Suppl. Sick Ins. 1.07% 0.88% 1.21% 0.00% 0.00% 0.00% Health & Welfare 16.13% 15.81% 16.01% 15.99% 16.70% 7.44% Small tools 2.00% 2.00% 0.00% 0.00% 0.00% 0.00% Safety/Training 4.00% 4.00% 4.00% 3.00% 0.00% 0.00% Supervision 67.10% 61.33% 32.23% 31.98% 19.32% 0.00% Force Acct. Ins. 23.00% 23.00% 23.00% 23.00% 0.00% 0.00% Funded Pension 0.00% 0.00% 0.00% 0.00% 0.00% 7.36% Composite Rate 154.49% 145.21% 116.13% 111.62% 80.60% 39.00% * Other included sick leave, personal leave, jury duty, bereavement, compassionate leave.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Suppl. SCR 762; All India Power Engineer Federation and Others v. Sasan Power Limited and Others (2017) 1 SCC 487 : [2016] 9 SCR 901; Xxxxxx International Ltd. v. I.V.R. Construction Ltd. and Others, (1999) 1 SCC 492 : [1998] 3 Suppl. SCR 421; Michigan Rubber (India) Limited v. State of Karnataka and Others D (2012) 8 SCC 216 : [2012] 8 SCR 128; Xxxxxxxx Xxxxx Xxxx and another v. Chief Election Commissioner, New Delhi and Others (1978) 1 SCC 405 : [1978] 2 SCR 272 – referred to. [2000] 1 Suppl. SCR 581 referred to Para 10 [1977] 3 SCR 249 referred to Para 11 (2004) 3 SCC 553 relied on Para 11 [2000] 1 SCR 925 relied on Para 18 (2022) 1 SCC 401 referred to Para 21 [1975] 2 SCR 674 referred to Para 27 (1972) 4 SCC 781 referred to Para 27 [1975] 3 SCR 254 referred to Para 27 [1979] 3 SCR 1014 relied on Para 29 [1989] 1 SCR 743 referred to Para 30 [1990] 1 SCR 818 referred to Para 31 Case Law Reference E G H [1996] 4 Suppl. SCR 762 referred to Para 35 [2001] 3 Suppl. SCR 112 referred to Para 36 [2005] 2 Suppl. SCR 421 referred to Para 37 [2003] 1 SCR 1174 referred to Para 39 [2007] 8 SCR 115 referred to Para 43 [2010] 7 SCR 908 relied on Para 47 [2015] 6 SCR 1042 referred to Para 49 [2015] 9 SCR 17 referred to Para 50 [1994] 2 Suppl. SCR 122 relied on Para 54(iv) [1996] 4 Suppl. SCR 762 referred to Para 54(viii) [1990] 1 Suppl. SCR 625 referred to Para 54(xii) [2016] 9 SCR 901 referred to Para 80 [1998] 3 Suppl. SCR 421 referred to Para 85 [2012] 8 SCR 128 referred to Para 86 [1978] 2 SCR 272 referred to Para 113 A [1990] 1 Suppl. SCR 625 relied on Para 32 B C D E CIVIL APPELLATE JURISDICTION: Civil Appeal Nos. 8515- 8516 of 2022. From the Judgment and Order dated 27.02.2020 of the High Court of Madhya Pradesh, Principal Seat at Jabalpur in W.P. No. 4205 of 2019 F and final Judgment and Order dated 28.12.2020 in Review Petition No. 682 of 2020.
Sample 1
Suppl. 239 (2), 35. doi: 10.3847/1538 -4365/aaee8c Xxxxxx, X., Xxxxx, X., Xxxx, M., Xxxxxxxx, M., & Xxxxxxxxx, V. (2016, May). Non- local gravity and comparison with observational datasets. ii. updated results and bayesian model comparison with cdm. Journal of Cosmology and Astroparticle Physics, 2016 (05), 068–068. Retrieved from xxxx://xx.xxx.xxx/10.1088/ 1475-7516/2016/05/068 doi: 10.1088/1475-7516/2016/05/068 Xx Xxxxxxxxx, X., Xxxx, D. E., Xxxxxxxxxx, X., & Xxxxx, F. (2018, October). The cos- mological impact of future constraints on H0 from gravitational-wave standard sirens. Physical Review D, 98 (8), 083523. doi: 10.1103/PhysRevD.98.083523 Xxxxxxxx, X. (2003). Modern cosmology. San Diego, CA: Academic Press. Retrieved from xxxxx://xxx.xxxx.xx/record/1282338 Xxxxxxxxx, X., Xxxx, X., Xxxxxxxxx, S., Xxxxxx, X., & Xxxxxxxxx, X. (2018, Febru- ary). Reconstruction of a direction-dependent primordial power spectrum from Xxxxxx CMB data. Journal of Cosmology and Astroparticle Physics, 2018 (2), 012. doi: 10.1088/1475-7516/2018/02/012 Xxxxxxxxx, X., Xxxx, P., Xxxxx, X., & Xxxxxx, S. (2019, October). Reconstructing the EFT of inflation from cosmological data. SciPost Physics, 7 (4), 049. doi: 10.21468/SciPostPhys.7.4.049 Xxxxx, X. X., Xxxxxxxxx, A. S., & Xxxxxxxx, C. (1920, January). A Determination of the Deflection of Light by the Sun’s Gravitational Field, from Observations Made at the Total Eclipse of May 29, 1919. Philosophical Transactions of the Royal Society of London Series A, 220 , 291-333. doi: 10.1098/rsta.1920.0009 Xxxxxxxx, X. (1987). Xxxx Xxxx, Xxxx xxx Xxxxxxx, and the Monte Carlo Method.
Sample 1
Suppl. 2007;51:s133-9. doi:10.1192/bjp.191.51.s133.
Sample 1
Suppl. 2:12-16 (1992). Olsson, C. A. et al., Immunologic reduction of bladder cancer recurrence rate. J. Urol. 111:173-176 (1974). Jurincic, C. D. et al., Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. J. Urol. 139:723-726 (1988). Flamx, X. et al., Recurrent superficial transitional cell carcinoma of the bladder: Adjuvant topical chemotherapy vs. immunotherapy. A prospective randomized trial. J. Urol. 144:260-263 (1990). Kilble, T. et al., Intravesticale rezidivprophylaze benign oberflachlichen harnblasenkarminom mit BCG und KLH. Urologic 30:118-121 (1991). Flamx, X. et al., Adjuvent topical chemotherapy versus immunotherapy is primary superficial transitional cell carcinoma of the bladder. Br. J. Urol. 67:70-73 (1991). Lamm, X. X. xx al., Immunotherapy of murine transitional cell carcinoma. J. Urol. 128:1104-1108 (1982). Lamm, X. X. xx al., Keyhole-limpet haemacyanin and immune ribonucleic acid immunotherapy of murine transitional cell carcinoma. Urol. Res. 9:237-230 (1981). Lamm, X. X. xx al., Immunotherapy of murine bladder cancer with keyhole-limpet. hemocyanin (K.L.H). J. Urol. 149:648-652 (1993). Laemmil, U. K., Clevage of structural proteins during the assembly of the head of bacteriophage T4. Nasure 227:680-685 (1970). Van Holde, K. E. et al., Boundary analysis of sedimentation-velocity experiments with ??? and ?? solutes. Biopolyn 17:1387-1403 (1978).
Sample 1
Suppl. 2:12-16 (1992).
Sample 1
Suppl. 4:22-24. 49 Moscow JA and Xxxxx XX. Multidrug resistance. Cancer Chemother. Biol. Response Modif. 11:978- 1114, 1990. 50 Juranka, P. F., Xxxxxxxx, X. X., and Ling, V. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J. 3:2583-2590. 51 Xxxx, X. X., Xxxx, X. X., Ueda, K., Xxxxx, X. X., Pastan, I., and Xxxxxxxxx, X. X., and Xxxxxxxx, X. X. Internal Duplication and homology with bacterial transport proteins in the mdrl (P-glycoprotein) gene from multidrug-resisrant human cells. Cell 47:381-389, 1986. 52 Van der Xxxxx, A. M., Xxxxxxx, P. M., Xxxxxxxxx, C., and Xxxxx, P. Sequence of mdr3 cDNA encoding a human P-glycoprotein. Gene 72:401-411, 1988. 53 Ro, J., Sahin, A., R, J.Y., Xxxxxxxx, H., Horfobagyi, G., and Blick, M. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Human Patholo. 21 :787-791, 1990. 54 Milckisch, G., Licht, T., Xxxxxxx, G., Xxxxxxxxx, M., and Pastan, I. Cancer Res. 51:5417, 1991. 55 Galski, H., Xxxxxxxx, M., Xxxxxxxxxx, M., Xxxx, X.X., Xxxxxxxxx, M., Pastan, I., and Xxxxxxx, G. Mol. Cell. Biol. 9:4357, 1989. 56 Mickisch, G., Xxxxxxx, G., Xxxxxx, H., Xxxxxxxxx, M., and Pastan, I. Proc. Natl. Acad. Sci. U.S.A. 88:549, 1991. 57 Pastan, I., Xxxxxxxxx, M., Neda, K., Xxxxxxxx, E., Xxxxxxxxxx, X.X., and Xxxxxxxxxx, M.C. Proc. Natl. Acad. Sci. U.S.A. 85:4486, 1988. 58 Xxxx, K., Frammel, T., Xxxxx, R., Xxxxx, C., Xxxxxxxx, M., Tsuruo, T., and Roninson, I. Proc. Natl. Acad. Sci. U.S.A. U.S.A.88:7386, 1991. 59 Xxxxxx, D. UCLA Conference on Genetic Therapy, Copper Mountain, Colorado, 1992.
Sample 1
AutoNDA by SimpleDocs
Suppl. 1 and 2 to 07; Corr.1 to 06 Rev.1/Add.16/Rev.3/Amend.4 30 Suppl.10 to 02 Rev.1/Add.29/Rev.2/Amend.1 Regulation No. Type of document Symbol: E/ECE/TRANS/5051 ... E/ECE/324 33 Suppl.1 to 00 Rev.1/Add.32/Rev.1/Amend.1 44 Suppl.2 to 03 Rev.1/Add.43/Rev.1/Amend.1
Sample 1
Suppl. 1:23-27 (2001).
Sample 1

Related to Suppl

  • Training Materials Training Materials will be provided for each student. Training Materials may be used only for either (i) the individual student’s reference during Boeing provided training and for review thereafter or (ii) Customer’s provision of training to individuals directly employed by the Customer.

  • Marketing Materials (a) During the term of this Agreement, the Sub-Adviser agrees to furnish the Manager at its principal office for prior review and approval by the Manager all written and/or printed materials, including but not limited to, PowerPointÒ or slide presentations, news releases, advertisements, brochures, fact sheets and other promotional, informational or marketing materials (the “Marketing Materials”) for internal use or public dissemination, that are produced or are for use or reference by the Sub-Adviser, its affiliates or other designees, broker-dealers or the public in connection with the Series, and Sub-Adviser shall not use any such materials if the Manager reasonably objects in writing within five business days (or such other period as may be mutually agreed) after receipt thereof. Marketing Materials may be furnished to the Manager by first class or overnight mail, facsimile transmission equipment, electronic delivery or hand delivery.

  • Products and Services General Information The Vendor Agreement (“Agreement”) made and entered into by and between The Interlocal Purchasing System (hereinafter “TIPS”) a government cooperative purchasing program authorized by the Region 8 Education Service Center, having its principal place of business at 0000 XX Xxx 000 Xxxxx, Xxxxxxxxx, Xxxxx 00000 and the TIPS Vendor. This Agreement consists of the provisions set forth below, including provisions of all attachments referenced herein. In the event of a conflict between the provisions set forth below and those contained in any attachment, the provisions set forth shall control unless otherwise agreed by the parties in writing and by signature and date on the attachment. A Purchase Order (“PO”), Agreement or Contract is the TIPS Member’s approval providing the authority to proceed with the negotiated delivery order under the Agreement. Special terms and conditions as agreed between the Vendor and TIPS Member should be added as addendums to the Purchase Order, Agreement or Contract. Items such as certificate of insurance, bonding requirements, small or disadvantaged business goals are some, but not all, of the possible addendums.

  • Supplies 1. Supplies are defined as consumable items necessary to carry out the services under this Contract including medical supplies, drugs, janitorial supplies, office supplies, patient educational supplies, software, and any items of tangible personal property other than those defined as equipment above.

  • Support Services HP’s support services will be described in the applicable Supporting Material, which will cover the description of HP’s offering, eligibility requirements, service limitations and Customer responsibilities, as well as the Customer systems supported.

  • Products Products available under this Contract are limited to Software, including Software as a Service, products and related products as specified in Appendix C, Pricing Index. Vendor may incorporate changes to their product offering; however, any changes must be within the scope of products awarded based on the posting described in Section 1.B above. Vendor may not add a manufacturer’s product line which was not included in the Vendor’s response to the solicitation described in Section 1.B above.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!